Using ChEMBL for target identification and prioritisation Open Targets Q&A on drug information in clinical trials as well as marketed drugs, provided by ChEMBL, for target identification and prioritisation.
Open Targets Platform Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
Open Targets Platform Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
Machine Learning Predicting Chemical Safety for Drug Discovery In this work, I illustrated the advantages of using multi‐label models for compounds toxicity assessment even when toxicity data is partially available.
Open Targets Platform On diseases and phenotypes, and how we learnt to stop worrying and ignore the distinction One of the questions that Open Targets Platform users ask is why we don't distinguish diseases from phenotypes. Ian Dunham tells us more in this blog post.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
Open Targets Platform Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Open Targets Genetics Open Targets Genetics new release is out We are pleased to announce the latest release of Open Targets Genetics is out with new colocalisation analysis, GWAS summary statistics and plenty more.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
Open Targets Platform Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Open Targets Genetics Open Targets Genetics: new release is out We are excited to announce we have a new release of Open Targets Genetics, a variant-centric resource to find diseases associations for drug discovery.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
genetic associations Adding a data source to the Open Targets Platform: an update In this post, I will give you an update on how to add a new data source to the Open Targets Platform following parts 1 and 2 published in 2018.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
Open Targets Platform Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
Open Targets Looking for cell line models to predict drug response in cancer patients? On this World Cancer Day, Hanna writes about Cellector, an open source tool for the selection of clinically relevant cancer cell lines for in vitro experiments.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. It's D-time.
Open Targets Platform Open Targets Platform: release 18.12 is out Our latest release of the Open Targets Platform is out. New data source - systems biology, new target tractability visualisation and more non-coding RNA genes.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Third in the series is C.
Open Targets Platform How to add a new data source to the Open Targets Platform, part 2 In this post, I will continue guiding you on how to add a new data source to the Open Targets Platform. This is part 2 of a 2-part series of posts.
genetic associations How to add a new data source to the Open Targets Platform - part 1 In this post, I will show you how to add a new data source to the Open Targets Platform. This is part 1 of a 2-part series of posts.
Open Targets Platform How to navigate the complexity of cancer genetics with the Cancer Gene Census Cancer is not a single disease, but a group of diseases underlined by extraordinary genetic complexity. How can cancer researchers navigate this complexity?
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Second in the series is B.
release notes Open Targets Platform: what's new in our latest release Our latest release of the Open Targets Platform is out. More targets, more evidence, more target-disease associations and a new prioritisation view.
